Order of the National Green Tribunal in the matter of News Item titled "2 killed in blast at illegal cracker unit in Thanjavur appearing in The Hindu dated 19.05.2025". The application is registered suo-motu on the basis of the news item titled 2 killed in blast at illegal cracker unit …
Big pharma has big incentives, including cost savings and more powerful studies, to launch trials in developing countries. But can companies avoid the ethical potholes?
Joe C Mathew / New Delhi October 3, 2008, 0:56 IST The World Health Organization (WHO) has given five more months to the Drugs Controller General of India (DCGI) to upgrade its performance to international standards. The extension of the current deadline of October-end came after a visiting WHO team …
Business Standard / New Delhi October 1, 2008, 0:09 IST One more round has started in the battle between drug patent holders and generics players with Swiss firm Hoffman-La Roche filing a patent infringement suit against Indian generics leader Cipla for launching a copy of its anti-infection drug Valcyte. This …
The performance of electrocoagulation method with aluminium, iron and hybrid A1/Fe sacrificial anodes in the treatment of arsenite [As9III) and arsenate(As(V)] in pharmaceutical industrial effluents was investigated. Several working parameters, such as pH, current density, contact time and metal ion concentration were studied in attempt to achieve optimum removal efficiency.
Bs Reporter / Chennai September 30, 2008, 0:08 ISTOrchid Chemicals and Pharmaceuticals today said that it has entered into an arrangement with US drug maker Merck & Co for the discovery and development of novel anti-infective drugs, which have a revenue potential of over $100 million.While the deal has been …
Last year, Anusha, 30, took a new weight-loss drug for seven months to combat her obesity. Although it helped her shed between 5 kg and 8 kg, she claims, there were side effects.
Bloomberg / Mumbai September 26, 2008, 0:14 IST American relief programme suspends funding for three generic medicines. AIDS drugs made by Ranbaxy Laboratories won't be purchased under an American programme to supply medicines to developing countries after the US cited the company for violations in two of its plants. The …
Daiichi Sankyo has said that there are procedural delays in completing the open offer for acquiring an additional 20% equity of Ranbaxy. The delay pertains to payments to shareholders who have subscribed to the Japanese company's open offer for acquiring an additional 20% equity of Ranbaxy. Daiichi will pay interest …
THE U.S. BAN ON some medicines made by India's largest pharmaceutical company adds a black mark against India's booming drug and drug-testing industries, which already have been under pressure over the country's lax monitoring of drug safety. India's pharmaceutical industry was once the nemesis of U.S. drug companies, producing knock-off …
Lapses on record-keeping Affects numerous, widely-used medications Preventive action to protect quality of drugs WASHINGTON: U.S. health officials have blocked dozens of drugs made by Ranbaxy Laboratories after the generic drugmaker failed to fix numerous record-keeping and other operational problems, although the medications themselves are considered safe. The U.S. Food …
Nina Mehta & Kiran Kabtta MUMBAI THE government has begun speeding up approvals in the area of clinical research which is set to boom in India, say top industry sources. The clinical research industry in India is currently $200 million, but is expected to reach $1.5 billion in just two …
P B Jayakumar / Mumbai September 12, 2008, 0:42 IST Avesta Biotherapeutics and Research (ABRPL), the 50:50 joint venture between Cipla group company Meditab Specialities and Bangalore-based Avestha Gengraine Technologies (Avesthagen), is targeting to launch about eight high-value, bio-similar or copied versions of off-patent biotech drugs before 2012. ABRPL is …
Joe C Mathew / New Delhi September 12, 2008, 0:23 IST An expert committee of the health ministry which looked into reviving three government vaccine units that were closed down has recommended converting two of these units into centres for producing yellow fever vaccine capable of serving global needs. The …
Rema Nagarajan | TIG If a disease can be treated for Rs 10, why would you spend Rs 12,000 for it? That is the question being raised by some doctors on a move to make a vaccine against pneumonia part of the immunisation programme. According to WHO protocol, pneumonia in …
Companiese that advertise prescription drugs directly to consumers may not get as much bang for their buck as they - or their critics - assume. Direct-to-consumer advertising (DTCA) of drugs is only permitted in the US and New Zealand and has long been controversial. Both proponents and opponents assume the …
As part of its foray into India, William Harvey Research -- the UK-based contract research organisation (CRO) and part of the renowned William Harvey Research Institute - is in discussions with three leading Indian pharmaceutical companies for joint drug research and collaborations. "We are looking at drug research alliances in …
Business Standard / New Delhi August 27, 2008, 1:02 IST A supportive eco-system is developing to ensure safety but since the system is by and large self-regulatory, it will be a while before it is fully secure. N K Ganguly, Former Director General, Indian Council of Medical Research These trials …
Joe C Mathew / New Delhi August 27, 2008, 0:39 IST Firm reaches out-of-court agreement on 5 of 19 patent challenges in the US. Ranbaxy Laboratories, India's largest pharmaceutical drug firm by sales, expects its recent patent litigation settlements to add significantly to its revenues as well as net profit. …
